Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 31, 2023

Management of Recurrent Ewing's Sarcoma With Vigil–Temozolomide–Irinotecan and Assessment of ctDNA

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Pilot Study of recurrent Ewing's Sarcoma management with Vigil/Temozolomide/Irinotecan and assessment of circulating tumor (ct) DNA
Clin. Cancer Res 2023 Mar 16;[EPub Ahead of Print], P Anderson, M Ghisoli, BD Crompton, KS Klega, LH Wexler, EK Slotkin, L Stanbery, L Manning, G Wallraven, M Manley, S Horvath, E Bognar, J Nemunaitis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading